IBA SA : IBA Signs Contract to Install Proton Therapy Center in China
29 Juin 2016 - 12:00PM
IBA Signs Contract
to Install Proton Therapy Center in China
Contract worth more than EUR 80 million
Louvain-La-Neuve,
Belgium, June 29, 2016 - IBA (Ion Beam Applications S.A.,
EURONEXT), the world's leading provider of proton therapy solutions
for the treatment of cancer, today announces that it has signed a
contract with Qingdao Zhong Jia Lian He Healthcare Management
Company Limited to install a Proteus®PLUS*
multi-room solution in Qingdao, Shandong Province, China. The
contract is worth more than EUR 80 million to IBA, including a long
term service contract.
IBA will equip the new center with
five treatment rooms, four isocentric-gantry treatment rooms and a
fixed-beam treatment room, including the latest generation of
precision technologies in Adaptive Intensity Modulated Proton
Therapy: Pencil Beam Scanning and Cone Beam CT. The contract
includes an operations and maintenance agreement and will also
provide all dosimetry equipment to ensure the safest and fastest
commissioning of the center. Qingdao Zhong Jia Lian He Healthcare
Management Company Limited expects to be treating patients at the
center by the end of 2018.
Olivier Legrain,
Chief Executive Officer of IBA, commented: "This new
collaboration with Qingdao Zhong Jia Lian He Healthcare Management
Company Limited further strengthens IBA's world leading position in
proton therapy. The Proteus®PLUS
proton therapy center in China will be one of the largest in the
world, as well as being one of the most technically advanced, with
the highest quality therapeutic and imaging capabilities. IBA is
pleased to be playing an important role in bringing such innovative
cancer treatment modalities to patients in China."
Wang Xiang Yu, of
Qingdao Zhong Jia Lian He Healthcare Management Company Limited
said: "We want to have the most innovative treatments for our
cancer patients in order to effectively fight this severe disease;
proton therapy will help give our team of oncologists the critical
tools to fight cancer. Our new Proteus®PLUS
multi-room solution, including Pencil Beam Scanning and Cone Beam
CT technology, will be installed by IBA and will allow us to
'paint' tumors with a super-fine beam of protons, destroying cancer
cells whilst leaving surrounding healthy tissue untouched."
***ENDS***
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The Company is the worldwide
technology leader in the field of proton therapy, the most advanced
form of radiation therapy available today. IBA's proton therapy
solutions are flexible and adaptable, allowing customers to choose
from universal full scale proton therapy centers as well as
compact, single room systems. In addition, IBA also has a
radiation dosimetry business and develops particle accelerators for
the medical world and industry.
Headquartered in Belgium and
employing about 1,300 people worldwide, IBA has installed systems
across the world, from Europe and the US and to the emerging
markets. IBA is listed on the pan-European stock exchange EURONEXT.
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information
can be found at: www.iba-worldwide.com
* Proteus®PLUS is the
brand name of a new configuration of the Proteus®235
About Qingdao
Zhong Jia Lian He Healthcare Management Company
Limited
Qingdao Zhong Jia Lian He Healthcare Management Company Limited is
a fully owned subsidiary of Hong Kong Zhong Jia Healthcare Group.
The company is responsible for building oncology Hospitals and
Class AAA General Hospitals throughout China; and will equip each
of them with Proton Therapy facilities. This Qingdao Hospital
investment including a Proton Therapy facility is worth 2 billion
Chinese Yuan.
For further information please
contact:
IBA
Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com |
For media and investor
enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Rx Communications Group (US)
Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com
|
290616-IBA-PR_ProteusPLUS-Qingdao-EN
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
HUG#2023857
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024